Perimenopause Emergency Symptoms Requiring 911

Which Symptoms Actually Require Calling 911

Perimenopause does not cause medical emergencies by itself, but women in their 40s and early 50s are at rising cardiovascular risk, and several life-threatening conditions can mimic or co-occur with perimenopause symptoms. Call 911 immediately for any of the following.

Chest Pain or Pressure With Shortness of Breath

Chest tightness, pressure, or pain radiating to the jaw, left arm, or back, especially when paired with shortness of breath or nausea, is a cardiac emergency until proven otherwise. Women having myocardial infarction are more likely than men to present with atypical features such as fatigue, indigestion, and upper back pain without classic crushing chest pain. The American Heart Association notes that cardiovascular disease kills more women each year than all cancers combined, and estrogen decline during perimenopause accelerates atherogenic changes in lipid profiles and vascular endothelium. [1]

Hot flashes can produce transient chest discomfort and palpitations, but those sensations are brief (typically 1 to 5 minutes), associated with flushing and sweating, and resolve spontaneously. Chest pain that persists beyond 5 minutes, worsens with exertion, or is accompanied by diaphoresis requires 911. Do not drive yourself to the emergency department.

Stroke Warning Signs: Act FAST

Sudden face drooping on one side, arm weakness (one arm drifts down when both are raised), or speech difficulty (slurred, absent, or confused speech) are the three FAST stroke criteria. Add a T for Time: call 911 immediately because the thrombolytic window for IV tPA closes at 3 to 4.5 hours from symptom onset per the 2019 AHA/ASA Stroke Guidelines. [2]

Sudden loss of vision in one eye, sudden severe vertigo with inability to stand, or sudden one-sided numbness also warrant a 911 call. These can represent transient ischemic attacks (TIAs) that precede stroke.

Sudden Severe "Thunderclap" Headache

A headache the patient describes as "the worst of my life" that reaches maximal intensity within 60 seconds is a subarachnoid hemorrhage until proven otherwise. This is not a migraine. Women with a history of perimenopausal migraines sometimes dismiss this presentation. Any sudden-onset severe headache with neck stiffness, photophobia, or vomiting requires 911 and urgent CT imaging.

Pulmonary Embolism Signs

One-sided leg pain and swelling followed by sudden shortness of breath, pleuritic chest pain (pain that worsens with breathing), or coughing up blood may indicate deep vein thrombosis progressing to pulmonary embolism. Women using oral estrogen-containing therapy carry approximately a 2-fold higher venous thromboembolism (VTE) risk compared with non-users; transdermal estradiol appears to carry a substantially lower VTE risk, though not zero. [3] Call 911 for any sudden unexplained shortness of breath.

Symptoms That Are Urgent but Not a 911 Emergency

Some perimenopause-related symptoms need medical attention within hours or the next business day, but they do not require emergency services.

Heavy Menstrual Bleeding

Soaking through a pad or tampon every hour for two consecutive hours, or passing clots larger than a golf ball, constitutes heavy menstrual bleeding (HMB). Call your clinician or go to urgent care. Persistent HMB can cause iron-deficiency anemia, and any new heavy bleeding after 12 months of amenorrhea (postmenopause) must be evaluated to rule out endometrial pathology. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 110 recommends endometrial sampling for women over 45 with abnormal uterine bleeding. [4]

Severe Mood Changes or Thoughts of Self-Harm

Perimenopause is associated with a two- to four-fold increase in the risk of a first major depressive episode compared with the premenopausal years, according to a prospective cohort study published in the Archives of General Psychiatry (N=460, followed across the menopausal transition). [5] Severe depression or any thoughts of suicide require same-day evaluation, not a scheduled appointment. Call or text 988 (Suicide and Crisis Lifeline) or go to the nearest emergency department.

New or Worsening Palpitations With Syncope

Brief palpitations during a hot flash are common. Palpitations that cause syncope (fainting), near-syncope, or last more than 30 seconds need same-day cardiac evaluation, including an ECG to rule out atrial fibrillation or other arrhythmia.

Understanding Normal Perimenopause Symptoms

Knowing what is expected helps a woman avoid unnecessary panic and recognize when something is genuinely abnormal.

Vasomotor Symptoms (Hot Flashes and Night Sweats)

Hot flashes are the hallmark of perimenopause. Up to 80% of women report them, and for 25 to 30% the severity is enough to affect daily functioning. [6] A typical flash lasts 1 to 5 minutes and is caused by hypothalamic thermoregulatory instability triggered by fluctuating estradiol. The Study of Women's Health Across the Nation (SWAN) followed over 3,300 women and found the median total duration of hot flash symptoms was 7.4 years, starting before the final menstrual period in most cases. [7]

Night sweats are the nocturnal form of the same phenomenon. They do not indicate infection or malignancy unless accompanied by unintentional weight loss, drenching sweats independent of temperature, or lymphadenopathy.

Cycle Irregularity and Defining the Menopausal Transition

The Stages of Reproductive Aging Workshop (STRAW+10) criteria define the early menopausal transition as cycles that vary by 7 or more days from the usual length, and the late transition as at least one interval of 60 or more days between periods. [8] Irregular cycles are expected; complete cessation of menses for 12 consecutive months defines menopause.

Cognitive and Sleep Changes

Self-reported memory complaints and difficulty concentrating are common during perimenopause. A cross-sectional analysis from the SWAN study found that perimenopausal women scored lower on tests of verbal memory and processing speed compared with premenopausal women, though the absolute decrement was modest and often reversed after the menopausal transition. Poor sleep from night sweats compounds perceived cognitive difficulty.

Why Cardiovascular Risk Rises During Perimenopause

Estrogen has vasodilatory and anti-inflammatory effects on the arterial wall. As estradiol levels become erratic and then decline, LDL-cholesterol typically rises 10 to 15%, HDL-cholesterol falls modestly, and blood pressure tends to increase. A longitudinal analysis of the SWAN Heart Study demonstrated that each unit increase in follicle-stimulating hormone (FSH) during the menopausal transition was associated with measurable increases in carotid intima-media thickness, an early marker of atherosclerosis. [9]

This is why symptoms that might be dismissed as "just perimenopause" in a 47-year-old can be cardiac or vascular events. A woman who smokes, has hypertension, diabetes, or a family history of early coronary artery disease should have a lower threshold for calling 911 with any chest or neurological symptom.

The HealthRX Perimenopause Triage Framework below summarizes the decision logic clinicians on our team use when advising patients on symptom urgency:

| Symptom | Action | |---|---| | Chest pain/pressure > 5 min, or with diaphoresis | Call 911 now | | Face droop, arm weakness, speech change | Call 911 now (FAST) | | Thunderclap headache | Call 911 now | | Sudden shortness of breath + leg swelling | Call 911 now | | Soaking >1 pad/hr for 2+ hours | Urgent care same day | | Palpitations with fainting | Urgent care / ER same day | | Severe depression or suicidal thoughts | 988 or ER same day | | Hot flashes, night sweats, irregular periods | Scheduled telehealth or in-person visit | | Mood changes, sleep disruption, brain fog | Scheduled visit within 2 weeks |

How to Manage Perimenopause: Evidence-Based Options

The goal of treatment is to reduce symptom burden and lower long-term health risks without introducing unacceptable new risks. Treatment selection depends on symptom severity, personal and family medical history, and patient preference.

Systemic Hormone Therapy

Systemic hormone therapy (HT) remains the most effective intervention for vasomotor symptoms. The 2022 Menopause Society (NAMS) Position Statement states: "For women aged younger than 60 years or within 10 years of menopause onset and without contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." [10]

The Women's Health Initiative (WHI) randomized controlled trial enrolled 16,608 women aged 50 to 79 and originally reported increased breast cancer risk with conjugated equine estrogen plus medroxyprogesterone acetate. Subsequent re-analysis restricted to women aged 50 to 59 who had initiated HT within 10 years of menopause showed a mortality benefit, not a risk, in the estrogen-alone arm (hazard ratio 0.69, 95% CI 0.51 to 0.94). [11] The timing hypothesis is now broadly accepted by the Endocrine Society and NAMS.

Transdermal estradiol (patches, gels, sprays) at doses of 0.025 to 0.1 mg/day bypasses hepatic first-pass metabolism and produces a lower VTE and stroke risk profile than oral estrogen. Women with a uterus require concomitant progestogen; micronized progesterone (Prometrium 100 to 200 mg nightly) has a more favorable breast risk profile than synthetic progestins based on observational data from the French E3N cohort (N=80,377). [3]

Low-Dose Oral Contraceptives for Perimenopausal Women

Women in the early menopausal transition who still need contraception and have no contraindications may use low-dose combined oral contraceptives (20 mcg ethinyl estradiol formulations). These suppress FSH spikes, reduce cycle irregularity, and control vasomotor symptoms. They are contraindicated in women over 35 who smoke, in those with hypertension, migraine with aura, or personal history of VTE or stroke, per the WHO Medical Eligibility Criteria for Contraceptive Use, 5th edition. [12]

Non-Hormonal Pharmacologic Options

For women who cannot or choose not to use hormones, several alternatives exist.

Fezolinetant (Veozah): The FDA approved this neurokinin 3 receptor antagonist in May 2023 at 45 mg daily for moderate-to-severe vasomotor symptoms. In the SKYLIGHT 1 trial (N=501), fezolinetant reduced the weekly frequency of moderate-to-severe hot flashes by 59% vs. 40% for placebo at week 12 (P<0.001). [13]

SSRIs and SNRIs: Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI for vasomotor symptoms. Venlafaxine 75 mg daily reduced hot flash frequency by approximately 60% vs. 27% for placebo in a randomized trial (N=80). [14] These agents are particularly useful when depression co-exists.

Gabapentin: At doses of 300 mg three times daily, gabapentin reduced hot flash frequency by 45% vs. 29% placebo in a randomized trial (N=59). [15] Sedation limits daytime use but makes it useful for night sweats.

Lifestyle Modifications

No randomized trial has shown that lifestyle changes eliminate hot flashes, but several reduce their frequency and improve overall perimenopausal health:

• Weight loss of 10 lbs or more was associated with a greater likelihood of hot flash remission in the MSPFLASH randomized trial.
• Regular aerobic exercise (150 minutes per week per AHA guidelines) reduces cardiovascular risk independently of HT.
• Core body temperature reduction via cooling the sleep environment, avoiding spicy food and alcohol, and using layered clothing can meaningfully reduce perceived flash severity.
• Cognitive behavioral therapy (CBT) reduced the problem rating of hot flashes by a standardized mean difference of 0.60 (95% CI 0.38 to 0.81) compared with control in a Cochrane meta-analysis of 8 trials. [16]

Contraindications to Hormone Therapy: Know Before You Start

HT is not appropriate for every perimenopausal woman. Absolute contraindications include:

• Personal history of estrogen receptor-positive breast cancer
• Active or recent VTE (deep vein thrombosis, pulmonary embolism)
• Active arterial thromboembolic disease (stroke, MI within the past year)
• Unexplained vaginal bleeding (must be evaluated before starting HT)
• Known or suspected estrogen-dependent malignancy
• Active liver disease with elevated transaminases

Women with controlled hypertension, a family history of breast cancer without personal history, obesity, or diabetes are not automatically excluded but require individualized risk-benefit discussion with a clinician experienced in menopause medicine. The Menopause Society's MenoPro app and the Endocrine Society's 2015 Clinical Practice Guideline on menopause both provide structured decision-support tools. [17]

Monitoring After Starting Hormone Therapy

Women starting systemic HT should have:

• Blood pressure checked at baseline and at 3 months (oral estrogen can slightly raise blood pressure in some individuals; transdermal generally does not)
• Fasting lipid panel at baseline and at 6 to 12 months
• Mammogram per age-appropriate screening guidelines (annual mammography from age 40 per the 2024 USPSTF recommendation, or earlier if high-risk)
• Endometrial assessment if any unexpected vaginal bleeding occurs on HT
• A structured 12-month review of symptom response and ongoing indication for therapy

There is no evidence-based maximum duration for HT in appropriate candidates. The 2022 NAMS Position Statement explicitly states that "arbitrary limits on duration" are not supported by current evidence. [10]

When to Call Your Clinician (Not 911, But Soon)

Several symptoms that arise during perimenopause warrant a scheduled or urgent call to your clinician:

• Any vaginal bleeding after 12 months of amenorrhea
• New onset of migraine with aura (reconsider estrogen-containing therapy)
• Breast mass or nipple discharge
• Unexplained weight loss of more than 10 lbs over 3 months
• Urinary incontinence interfering with daily life
• Dyspareunia (painful intercourse) severe enough to avoid sexual activity
• Symptoms of hypothyroidism (fatigue, weight gain, cold intolerance, constipation) which closely mimic perimenopause and require a TSH measurement to distinguish

The American Thyroid Association reports that approximately 5% of women aged 40 to 60 have overt hypothyroidism; subclinical hypothyroidism affects an additional 10% of this group. A single TSH blood test takes 5 minutes and should be ordered at the first perimenopausal workup. [18]